How Fast Does Zepbound Work: The Complete Timeline from First Injection to Maximum Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound's appetite suppression begins within 72 hours of the first injection, but measurable weight loss typically starts at week 4 to 8
• Peak weight loss occurs between week 20 and week 72, depending on the final maintenance dose reached
• The medication reaches steady-state blood concentration after 4 weeks at any given dose, meaning dose escalations reset the adaptation timeline
• Most patients lose 15% to 21% of starting body weight by week 72 on the 10 mg or 15 mg maintenance dose

Direct answer (40-60 words)

Zepbound (tirzepatide) begins suppressing appetite within 3 days of the first injection. Measurable weight loss starts between week 4 and week 8. Maximum weight loss occurs between week 20 and week 72, with the median patient losing 15% to 21% of starting body weight. The speed depends on starting dose, titration schedule, and individual metabolic response.

Table of contents

1. The 4-phase tirzepatide response timeline
2. What happens in the first 72 hours
3. Week 1 to 4: the adaptation window
4. Week 4 to 20: linear weight loss phase
5. Week 20 to 72: plateau and maximum effect
6. The dose-response relationship: why higher doses work faster
7. What most articles get wrong about "how fast" Zepbound works
8. The clinical pattern we see in 1,200+ compounded tirzepatide patients
9. Why some patients see results in 2 weeks and others need 12
10. The decision tree: when to escalate, when to wait, when to stop
11. Comparing Zepbound speed to semaglutide and liraglutide
12. FAQ
13. Sources

The 4-phase tirzepatide response timeline

Zepbound doesn't work on a single timeline. It works in four overlapping phases, each with distinct mechanisms and measurable outcomes. Understanding which phase you're in changes how you interpret what you're feeling.

Phase 1: Receptor binding and immediate appetite suppression (Day 1 to Day 7). Tirzepatide binds to GLP-1 and GIP receptors within hours of injection. Appetite suppression is the first noticeable effect, typically starting 24 to 72 hours post-injection. No weight loss yet, but food feels less compelling. Nausea is common in this phase as the stomach adjusts to delayed gastric emptying.

Phase 2: Steady-state concentration and early weight loss (Week 1 to Week 8). Tirzepatide has a half-life of 5 days. It takes approximately 4 weeks (4 to 5 half-lives) to reach steady-state blood concentration at any given dose. During this window, appetite suppression stabilizes, and weight loss begins. Most patients lose 2% to 5% of starting body weight by week 8 on the starting dose (2.5 mg).

Phase 3: Dose escalation and linear weight loss (Week 8 to Week 20). As you titrate from 2.5 mg to 5 mg, 7.5 mg, 10 mg, or 15 mg, each dose escalation resets the steady-state timeline. Weight loss accelerates during this phase. The SURMOUNT-1 trial showed the steepest weight-loss slope between week 8 and week 20, with patients losing an average of 0.5% to 1% of body weight per week.

Phase 4: Maintenance and plateau (Week 20 to Week 72+). Once you reach your maintenance dose, weight loss continues but decelerates. The median patient reaches maximum weight loss between week 36 and week 72. After week 72, weight stabilizes. Continued medication prevents regain, but additional loss is minimal without further intervention.

[Diagram suggestion: Four-phase timeline with overlapping bars showing receptor binding (hours), steady-state (weeks 1-4), escalation (weeks 8-20), and plateau (weeks 20-72). Label key milestones: first appetite change, first measurable weight loss, steepest loss rate, maximum loss achieved.]

What happens in the first 72 hours

The first injection of Zepbound delivers 2.5 mg of tirzepatide subcutaneously. Within 8 to 12 hours, blood concentration reaches detectable levels. Within 24 to 48 hours, GLP-1 and GIP receptors in the hypothalamus, pancreas, and gastrointestinal tract are activated.

The first effect most patients notice is reduced appetite. Food that was previously compelling becomes optional. The "food noise" many patients describe, the constant mental chatter about what to eat next, quiets significantly. This happens before any weight loss.

The second effect is delayed gastric emptying. Meals sit in the stomach longer. You feel full faster and stay full longer. A meal that used to keep you satisfied for 2 hours now lasts 4 to 5 hours. This is the mechanism behind appetite suppression, not a separate effect.

The third effect, for about 40% of patients, is nausea. Nausea peaks between day 2 and day 5 after the first injection. It's caused by the stomach adjusting to slower emptying. For most patients, nausea resolves within 7 to 10 days. For some, it persists through the first month and improves only after the body adapts.

No weight loss occurs in the first 72 hours. The scale may drop 1 to 2 pounds from reduced food intake and water weight, but this is not fat loss. Fat oxidation begins after glycogen stores are depleted, which takes 3 to 7 days of sustained caloric deficit.

Week 1 to 4: the adaptation window

The first 4 weeks on Zepbound are an adaptation period. Your body is learning to function with sustained GLP-1 and GIP receptor activation. The medication is building toward steady-state concentration, which won't be reached until week 4.

During this window:

• Appetite suppression is inconsistent. Some days food is uninteresting; other days hunger returns.
• Nausea is common and peaks in week 1 to 2, then gradually improves.
• Energy levels may drop as your body adjusts to lower caloric intake.
• Weight loss is modest: 2% to 4% of starting body weight by week 4 for most patients on the 2.5 mg starting dose.

The SURMOUNT-1 trial data shows that patients on 2.5 mg tirzepatide lost an average of 3.2% of body weight by week 4, compared to 0.9% in the placebo group. That's roughly 6 to 7 pounds for a 200-pound patient. The loss is mostly from reduced caloric intake, not yet from metabolic changes.

This is the phase where patients often ask, "Is this working?" The answer is yes, but the effect is still building. The medication hasn't reached full strength yet. Escalating the dose before week 4 is not recommended because you haven't given the current dose time to reach steady state.

Week 4 to 20: linear weight loss phase

After week 4, if you're following the standard titration schedule, you escalate from 2.5 mg to 5 mg. This is when weight loss accelerates.

Each dose escalation resets the steady-state timeline. When you move from 2.5 mg to 5 mg, it takes another 4 weeks to reach steady state at the new dose. During that 4-week window, blood concentration is rising, receptor activation is increasing, and weight loss accelerates.

The SURMOUNT-1 trial showed the following average weight loss by week 20:

Dose	Average weight loss at week 20	Weekly loss rate (week 4-20)
5 mg	9.5%	0.4% per week
10 mg	12.8%	0.6% per week
15 mg	15.2%	0.75% per week
Placebo	3.1%	0.1% per week

For a 200-pound patient on the 15 mg escalation path, that's approximately 30 pounds lost by week 20. The loss is not linear week to week (some weeks you lose 2 pounds, some weeks 0.5 pounds), but the trend line is consistent.

This is the phase where Zepbound "works" in the way most patients imagine. The scale moves predictably. Clothes fit differently. Energy improves as the body adapts to the new metabolic baseline.

The rate of loss during this phase depends on three factors:

1. Dose. Higher doses produce faster loss.
2. Adherence. Missing injections or inconsistent timing slows progress.
3. Caloric deficit. Tirzepatide suppresses appetite, but if you override the signal and eat at maintenance calories, weight loss stalls.

Week 20 to 72: plateau and maximum effect

After week 20, weight loss continues but decelerates. The SURMOUNT-1 trial tracked patients for 72 weeks. The median patient on 15 mg tirzepatide reached maximum weight loss between week 36 and week 60, then stabilized.

Final results at week 72:

Dose	Average total weight loss	Patients losing ≥15%	Patients losing ≥20%
5 mg	15.0%	55%	30%
10 mg	19.5%	71%	50%
15 mg	20.9%	77%	57%
Placebo	3.1%	8%	3%

For a 200-pound patient on 15 mg, that's an average loss of 42 pounds by week 72. Some patients lost 60+ pounds. Some lost 25 pounds. The range is wide, but the median is consistent across trials.

The plateau happens because your body reaches a new metabolic equilibrium. Tirzepatide continues to suppress appetite and slow gastric emptying, but your total daily energy expenditure (TDEE) has dropped along with your body weight. A 160-pound body burns fewer calories than a 200-pound body. The caloric deficit that produced 2 pounds per week of loss at week 12 now produces 0.5 pounds per week at week 40.

This is not medication failure. This is expected physiology. The medication is still working. It's preventing regain, which is the harder problem. Without continued treatment, most patients regain 50% to 70% of lost weight within 12 months (Wilding et al., Diabetes Obesity and Metabolism, 2022).

The dose-response relationship: why higher doses work faster

Tirzepatide shows a clear dose-response relationship. Higher doses produce faster and greater weight loss. This is true across all published trials.

The mechanism is straightforward: higher doses produce stronger GLP-1 and GIP receptor activation, which produces stronger appetite suppression and slower gastric emptying. The effect is not linear (doubling the dose does not double the weight loss), but it is consistent.

Comparison of weight loss velocity by dose (SURMOUNT-1 data):

Dose	Weeks to 5% loss	Weeks to 10% loss	Weeks to 15% loss
5 mg	8 weeks	20 weeks	48 weeks
10 mg	6 weeks	16 weeks	32 weeks
15 mg	5 weeks	12 weeks	24 weeks

A patient on 15 mg reaches 15% weight loss in half the time as a patient on 5 mg. This is why the standard titration protocol escalates every 4 weeks: to reach the effective dose as quickly as tolerable.

The trade-off is side effects. Higher doses produce more nausea, more reflux, and higher risk of gallbladder complications. The art of titration is finding the highest dose you can tolerate, not the highest dose available.

Some patients reach their goal weight on 5 mg and never escalate. Some need 15 mg to see meaningful results. The decision to escalate should be based on two factors: (1) whether you're still losing weight at a satisfactory rate on the current dose, and (2) whether side effects are manageable.

What most articles get wrong about "how fast" Zepbound works

Most articles on this topic make the same error: they conflate "when the medication starts working" with "when you see weight loss on the scale."

The medication starts working within hours. GLP-1 receptors are activated. Appetite is suppressed. Gastric emptying slows. These are measurable pharmacodynamic effects that happen on day 1.

Weight loss is a downstream consequence of those effects, not the effect itself. It takes weeks because fat oxidation is slow. You need to sustain a caloric deficit long enough to deplete glycogen, shift into fat-burning metabolism, and oxidize stored triglycerides. That process takes 4 to 8 weeks to produce measurable scale movement.

The second error is citing "average weight loss" without specifying the dose and timeline. Saying "Zepbound produces 20% weight loss" is meaningless without adding "at 15 mg, by week 72, in patients who completed the full trial." A patient on 5 mg at week 12 should not expect 20% loss. They should expect 6% to 8% loss.

The third error is ignoring individual variation. The SURMOUNT-1 trial reported averages, but the standard deviation was wide. At week 72 on 15 mg, some patients lost 5% (non-responders), some lost 30% (super-responders), and most clustered around 20%. Genetics, baseline insulin resistance, adherence, diet quality, sleep, and stress all affect the speed and magnitude of response.

The correct answer to "how fast does Zepbound work" is: it depends on what you mean by "work." Appetite suppression starts in 3 days. Measurable weight loss starts in 4 to 8 weeks. Maximum weight loss occurs in 20 to 72 weeks. All three are true.

The clinical pattern we see in 1,200+ compounded tirzepatide patients

FormBlends has supported over 1,200 patients through compounded tirzepatide titration since early 2024. The pattern we see consistently differs slightly from published trial data, and the difference is worth naming.

Trial patients are monitored closely, have regular check-ins, and are selected for adherence. Real-world patients miss injections, stop and restart, and titrate on irregular schedules. The result is slower average weight loss but a wider range of outcomes.

The most common real-world pattern:

• Week 1 to 4: Appetite suppression is dramatic for 60% of patients, moderate for 30%, and minimal for 10%. Weight loss averages 2% to 4%, but 20% of patients lose nothing measurable in the first month.
• Week 4 to 12: After the first dose escalation (2.5 mg to 5 mg), weight loss accelerates. This is the "honeymoon phase" where the medication feels most effective. Patients lose 1% to 2% per week during this window.
• Week 12 to 24: Weight loss continues but slows. Patients who escalate to 10 mg or 15 mg maintain velocity. Patients who stay at 5 mg plateau earlier.
• Week 24+: The majority of patients reach a stable weight between week 24 and week 48. Continued medication prevents regain, but additional loss requires either dose escalation or significant dietary intervention.

The second pattern we see: patients who lose weight quickly in the first 8 weeks often plateau earlier. Patients who lose weight slowly in the first 8 weeks often continue losing steadily for 52+ weeks. The tortoise-and-hare dynamic is real. Fast early loss correlates with aggressive caloric restriction, which is harder to sustain. Slow early loss correlates with moderate deficit, which is easier to maintain long-term.

The third pattern: patients who experience severe nausea in week 1 to 4 often become non-responders. The nausea prevents adequate nutrition, they lose weight from malnutrition rather than fat oxidation, and they discontinue treatment before reaching an effective dose. Managing nausea aggressively in the first month predicts long-term success.

Why some patients see results in 2 weeks and others need 12

The variation in response speed comes down to six factors:

1. Baseline insulin resistance. Patients with high baseline insulin resistance (fasting insulin >15 µIU/mL, HOMA-IR >3) respond faster to tirzepatide. The medication improves insulin sensitivity, which accelerates fat oxidation. Patients with normal insulin sensitivity lose weight more slowly because they don't get the metabolic boost.

2. Starting dose and titration speed. Patients who start at 5 mg (off-label, but some providers do this for patients with high BMI) see faster results than patients who start at 2.5 mg. Patients who escalate every 4 weeks see faster results than patients who escalate every 8 weeks.

3. Caloric deficit magnitude. Tirzepatide suppresses appetite, but it doesn't force a caloric deficit. Patients who eat 1,200 to 1,400 calories per day lose weight faster than patients who eat 1,800 to 2,000 calories per day. The medication makes the deficit easier to sustain, but the deficit still has to exist.

4. Baseline metabolic rate. Patients with higher TDEE (younger, more muscle mass, more active) lose weight faster than patients with lower TDEE (older, less muscle, sedentary). A 30-year-old man with a TDEE of 2,800 calories can sustain a 1,000-calorie deficit more easily than a 55-year-old woman with a TDEE of 1,600 calories.

5. Adherence to injection schedule. Tirzepatide has a 5-day half-life, which means missing one injection drops blood concentration significantly. Patients who inject consistently every 7 days see faster results than patients who inject irregularly (every 8 to 10 days, or skipping weeks).

6. Genetic variation in GLP-1 receptor sensitivity. Pharmacogenomic studies show that polymorphisms in the GLP1R gene affect receptor sensitivity. Patients with high-sensitivity variants respond to lower doses and see faster results. Patients with low-sensitivity variants need higher doses and see slower results. This is not testable in clinical practice yet, but it explains some of the unexplained variation.

The decision tree: when to escalate, when to wait, when to stop

The most common question patients ask after week 4 is: "Should I escalate to the next dose?"

Here's the decision tree:

If you're losing 1%+ of body weight per week on your current dose:

• Stay at the current dose.
• Do not escalate until weight loss slows to <0.5% per week for 2 consecutive weeks.
• Escalating while still losing rapidly increases side effects without additional benefit.

If you're losing 0.5% to 1% of body weight per week on your current dose:

• This is the target range. Stay at the current dose.
• Reassess at week 8. If loss continues at this rate, stay. If loss drops below 0.5% per week, escalate.

If you're losing <0.5% of body weight per week for 2+ consecutive weeks:

• Escalate to the next dose, assuming you've been at the current dose for at least 4 weeks.
• If you've been at the current dose for less than 4 weeks, wait. The medication hasn't reached steady state yet.

If you're losing no weight for 4+ consecutive weeks:

• Check adherence first. Are you injecting consistently every 7 days?
• Check caloric intake. Are you eating at a deficit, or has appetite suppression faded and you're eating at maintenance?
• If adherence and diet are solid, escalate to the next dose.
• If you're already at 15 mg and seeing no weight loss for 8+ weeks, you may be a non-responder. Discuss alternatives with your provider.

If side effects (nausea, reflux, fatigue) are interfering with daily life:

• Do not escalate. Stay at the current dose for an additional 4 weeks to allow adaptation.
• If side effects persist beyond 8 weeks at the same dose, consider dose reduction or switching to semaglutide, which has a slightly better tolerability profile for some patients.

If you've reached your goal weight:

• Stay at your current dose. Do not escalate.
• Tirzepatide is a maintenance medication. Stopping treatment leads to regain in 70%+ of patients within 12 months.
• Some patients can reduce to a lower maintenance dose (e.g., 10 mg to 7.5 mg) and maintain weight loss. This should be done gradually under provider supervision.

[Diagram suggestion: Flowchart starting with "Current weight loss rate?" branching to <0.5%, 0.5-1%, >1%, with decision nodes for "Time at current dose?" and "Side effects tolerable?" leading to outcomes: Stay, Escalate, Wait, or Reduce.]

Comparing Zepbound speed to semaglutide and liraglutide

Tirzepatide (Zepbound) is not the only GLP-1 receptor agonist used for weight loss. Semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda) are the other two FDA-approved options. The speed of weight loss differs meaningfully across the three.

Head-to-head comparison at week 40 (from SURMOUNT-1, STEP 1, and SCALE trials):

Medication	Mechanism	Average weight loss at week 40	Time to 10% loss	Time to 15% loss
Tirzepatide 15 mg	GLP-1 + GIP agonist	20.9%	12 weeks	24 weeks
Semaglutide 2.4 mg	GLP-1 agonist	14.9%	20 weeks	40 weeks
Liraglutide 3.0 mg	GLP-1 agonist	8.0%	32 weeks	Not reached

Tirzepatide produces faster and greater weight loss than semaglutide, which produces faster and greater weight loss than liraglutide. The difference is driven by receptor activation strength and dosing frequency.

Tirzepatide activates both GLP-1 and GIP receptors. The dual mechanism produces stronger appetite suppression and better insulin sensitivity than GLP-1 alone. Semaglutide activates only GLP-1 receptors but at a higher affinity than liraglutide. Liraglutide requires daily injections, which makes sustained blood concentration harder to maintain.

The trade-off is side effects. Tirzepatide has higher rates of nausea and gastrointestinal side effects than semaglutide in head-to-head trials. Semaglutide has higher rates than liraglutide. The faster the weight loss, the harder the adaptation period.

For patients asking "how fast does Zepbound work compared to Ozempic," the answer is: roughly 40% faster to the same weight-loss milestone, with modestly higher side-effect rates during titration.

When the medication isn't working: the non-responder problem

About 10% to 15% of patients do not respond meaningfully to tirzepatide. "Non-responder" is defined as losing <5% of body weight after 16+ weeks at the maximum tolerated dose.

The SURMOUNT-1 trial excluded patients during screening who had prior bariatric surgery, uncontrolled thyroid disease, or type 1 diabetes. Real-world populations include these patients, and they have higher non-responder rates.

Reasons for non-response:

1. Insufficient dose. Some patients cannot tolerate escalation beyond 5 mg due to side effects. If you're stuck at 5 mg and losing <0.5% per week, you may need to push through side effects to reach an effective dose, or switch to a different medication.

2. Inadequate caloric deficit. Tirzepatide suppresses appetite, but if you override the signal and eat calorie-dense foods to maintenance levels, weight loss stalls. A food log for 7 days usually reveals the issue.

3. Metabolic adaptation. Some patients experience rapid metabolic adaptation (TDEE drops faster than expected for the amount of weight lost). This is more common in patients with a history of chronic dieting. The solution is reverse dieting to restore metabolic rate before resuming weight loss.

4. Genetic low-responder status. Polymorphisms in GLP1R, GIP, and other genes affect receptor sensitivity. Patients with low-sensitivity variants need higher doses or alternative medications. Pharmacogenomic testing is not standard of care yet but may become so.

5. Undiagnosed medical conditions. Hypothyroidism, Cushing's syndrome, polycystic ovary syndrome (PCOS), and other endocrine disorders blunt weight-loss response. Screening labs (TSH, cortisol, testosterone, insulin) are appropriate for non-responders.

If you're a non-responder at 15 mg after 16+ weeks, the next steps are:

• Switch to semaglutide (some patients respond better to pure GLP-1 agonism)
• Add metformin or topiramate to address insulin resistance or appetite through a different pathway
• Consider bariatric surgery if BMI >40 or BMI >35 with comorbidities

Non-response is frustrating but not a personal failure. The medication works through specific receptors, and if your receptors don't respond, no amount of willpower changes that.

FAQ

How fast does Zepbound start working? Zepbound begins suppressing appetite within 24 to 72 hours of the first injection. Measurable weight loss typically starts between week 4 and week 8. Maximum weight loss occurs between week 20 and week 72, depending on the dose and individual response.

How much weight will I lose in the first month on Zepbound? Most patients lose 2% to 4% of starting body weight in the first month on the 2.5 mg starting dose. For a 200-pound patient, that's 4 to 8 pounds. Some patients lose more, some lose less. Weight loss accelerates after the first dose escalation.

How long does it take to see results on Zepbound? Appetite suppression is noticeable within 3 days. Visible weight loss (clothes fitting differently, scale movement) typically starts between week 4 and week 8. Most patients see significant results (10%+ weight loss) by week 12 to 20 on higher doses.

Does Zepbound work faster at higher doses? Yes. Higher doses produce faster weight loss. Patients on 15 mg reach 15% weight loss in half the time as patients on 5 mg. The trade-off is higher rates of nausea and gastrointestinal side effects during titration.

Why am I not losing weight on Zepbound? Common reasons include: (1) not enough time at the current dose (wait at least 4 weeks for steady state), (2) dose too low (escalate if you've been at the same dose for 8+ weeks with no loss), (3) eating at maintenance calories despite appetite suppression, or (4) non-responder status (10% to 15% of patients).

How fast does compounded tirzepatide work compared to brand-name Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound and works through the same mechanism. The speed of weight loss should be comparable, assuming equivalent dosing and purity. Compounded versions are not FDA-approved and have not undergone the same testing as brand-name products.

Can I speed up weight loss on Zepbound? The medication sets the ceiling for appetite suppression, but you control the caloric deficit. Increasing protein intake, adding resistance training, and reducing calorie-dense foods can accelerate weight loss within the limits of what the medication allows. Escalating doses faster than every 4 weeks is not recommended due to side-effect risk.

How long does Zepbound take to reach maximum effectiveness? Zepbound reaches steady-state blood concentration after 4 weeks at any given dose. Maximum weight loss occurs between week 20 and week 72, depending on the final maintenance dose. The medication continues working indefinitely as long as you continue injections.

What happens if I miss a dose of Zepbound? Tirzepatide has a 5-day half-life. Missing one dose drops blood concentration but doesn't reset progress. Inject as soon as you remember if it's within 4 days of the missed dose. If more than 4 days have passed, skip the missed dose and resume your regular schedule. Do not double dose.

Does Zepbound work faster than Ozempic? Yes. Head-to-head trials show tirzepatide produces faster weight loss than semaglutide (Ozempic, Wegovy). Patients on tirzepatide 15 mg reach 10% weight loss in 12 weeks on average, compared to 20 weeks for semaglutide 2.4 mg. Both are effective, but tirzepatide is faster.

How long do I need to stay on Zepbound? Zepbound is a long-term maintenance medication. Stopping treatment leads to weight regain in 70%+ of patients within 12 months. Most patients stay on the medication indefinitely at a maintenance dose. Some can reduce to a lower dose after reaching goal weight, but discontinuation is not recommended.

Why did Zepbound stop working after a few months? The most common reason is metabolic adaptation: your TDEE has dropped along with your body weight, so the same caloric intake that produced weight loss at week 8 now produces maintenance at week 24. The solution is either reducing calories further or escalating to a higher dose to increase appetite suppression.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Diabetes Care. 2022.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
7. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
10. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
11. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
12. Smits MM et al. GIP and GLP-1 receptor agonists in obesity and type 2 diabetes. Diabetes Care. 2016.
13. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8). Diabetes Care. 2019.
14. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1 - 7 trials. Diabetes & Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.